Jyong Biotech
MENS
19 hedge funds and large institutions have $1.01M invested in Jyong Biotech in 2026 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 5 increasing their positions, 9 reducing their positions, and 3 closing their positions.
67% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 3
44% more capital inflows, than outflows
Capital inflows: $233K | Capital outflows: $161K
12% more funds holding
Funds holding: 17 → 19 (+2)
0.05% more ownership
Funds ownership: 0.6% → 0.64% (+0.05%)
44% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HRT Financial
New York
|
+$82K |
| 2 |
XTX Topco
George Town,
Cayman Islands
|
+$61.7K |
| 3 |
Renaissance Technologies
New York
|
+$48.6K |
| 4 |
State of Wyoming
Cheyenne,
Wyoming
|
+$23.8K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$9.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$70.7K |
| 2 |
Millennium Management
New York
|
-$31.4K |
| 3 |
Vanguard Personalized Indexing Management
Oakland,
California
|
-$29.9K |
| 4 |
Tower Research Capital (TRC)
New York
|
-$22.6K |
| 5 |
China Universal Asset Management Company
Shanghai,
China
|
-$2.28K |
MENS Hedge Fund Activity: Q2 2026 in Review
19 of the 8,367 institutional investors tracked by Wall St. Rank reported a position in Jyong Biotech (MENS) for Q2 2026, worth a combined $1.01M — up 3.8% from $974K a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new MENS positions and 3 closed out — a net gain of 2 holders — while 5 added to existing stakes and 9 trimmed.
The largest buyer was HRT Financial, adding an estimated $82K. The largest seller was UBS Group, cutting an estimated $70.7K.
- 19 institutional investors held Jyong Biotech (MENS) as of Q2 2026, up from 17 in Q1 2026.
- Funds reported $1.01M of Jyong Biotech stock for Q2 2026, up 3.8% quarter-over-quarter.
- 5 funds opened new Jyong Biotech positions in Q2 2026 and 3 closed out, a net change of +2 holders.
- The largest Jyong Biotech buyer in Q2 2026 was HRT Financial, an estimated $82K added.
- The largest Jyong Biotech seller in Q2 2026 was UBS Group, an estimated $70.7K sold.
Based on aggregated 13F filings for Q2 2026.